🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Working on getting a bibliography of sorts for psychedelic ethics/philosophy papers together - sharing in case it comes in useful for anyone else! Ongoing project & please feel free to let me know if I've missed something 🌿 katcheung.com/psychedelic-et…

Very much reassured that numerous psychedelic researchers can come together and consider the much overlooked potential risk and harm of psychedelics too, and delighted to be among them. Maximising benefits is about minimising harms, and there are many potential benefits..

We are pleased to sponsor 5 free registrations to ISRP for those that are facing barriers to attendance. See below for more information and to apply.

Colorado began accepting license applications for its psychedelics program on Dec 31, 2024. It appears to be quite a slow start, with only a half-dozen or so ‘standard’ service/healing centre license applications and three ‘micro’ ones. More: psychedelicalpha.com/news/p%ce%b1-p…

Viewpoint discusses challenges related to ketamine use within psychiatry and offers recommendations for optimizing patient safety. ja.ma/4jZihe0

Paper I am happy to have contributed to with Brian Barnett and many others, “Practical considerations in the establishment of psychedelic research programs”. Open access, everything people need to know. link.springer.com/article/10.100…

IMO many debates in the medical literature, like the efficacy of #SSRI, are due to not understanding the difference between - WITHIN-ARM effect, i.e how much patients improved in the given arm and - BETWEEN-ARM effect, i.e how much better treatment did relative to placebo See

With Caleigh Propes (she/her), Eddie Talks Drugs, Brian D. Earp, Ph.D. & David B. Yaden, we’re happy to share HOPE’s (HOPE) response to the PATH Caucus's Request for Information (RFI) on psychedelic research for mental health (linked below) 🧵

In our response, we reviewed a number of issues, incl. guidance documents for supervision of dosing sessions, adverse event collection, insurance reimbursement & accessibility, & participant protection. Across these areas, we found a lack of guidelines & standards for the field.

We thus call for: 1) The establishment of a Psychedelic Standards and Solutions Committee (PSSC), to develop national standards and guidelines 📝 2) Enhanced federal support in the form of NIH & other governmental funding to help drive sustainable progress & rigorous research 🔬

We hope that establishment of the PSSC will help to unify the field, reduce regulatory inconsistencies, and facilitate the safe integration of psychedelics into mainstream healthcare.

Link to our Response here: researchgate.net/publication/38…

Link to Path Caucus RFI: congress.gov/118/crec/2024/…

We’re happy to share HOPE’s (HOPE) response to the PATH Caucus’s Request for Information (RFI) on psychedelics. Our response, linked below, highlights key considerations for the field. Katherine Cheung, Caleigh Propes (she/her), Eddie Talks Drugs, Brian D. Earp, Ph.D., & David B. Yaden

Enhanced independence: De-biasing processes in psychedelic research and beyond - Katherine Cheung, Rebecca Ehrenkranz, David B. Yaden, 2025 journals.sagepub.com/doi/10.1177/17…

As the field progresses, we argue that psychedelic research can work towards improving its rigor and transparency by adopting Open Science practices, as well as learning from methods that have been applied in other settings (e.g. in industry-sponsored trials) to mitigate bias.

New in Research Ethics: "Enhanced independence: De-biasing processes in psychedelic research and beyond" RCTs aren't immune to bias—and perceived bias in psychedelic trials is an issue. Katherine Cheung Rebecca Ehrenkranz, PhD, MPH @existwell propose 4 independence-enhancing practices: -

CPCR faculty David Yaden (David B. Yaden) spoke with Johns Hopkins Medicine (Johns Hopkins Medicine) to discuss evidence-based messaging about psychedelic research, informed consent, and adverse events surveillance.

An aficionado of the hype cycle—and, for that matter, the post-hype comedown—associated with promising new mental health treatments, Raison is perhaps uniquely positioned to weigh in on the current state and future prospects of psychedelics in mainstream psychiatry...

Excited to have a piece coming out with a 90 year update on my grandfather’s work - check this out: